Title |
Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report
|
---|---|
Published in |
Drug Safety - Case Reports, February 2018
|
DOI | 10.1007/s40800-018-0074-3 |
Pubmed ID | |
Authors |
Mesut Yilmaz, Canan Yasar, Selda Aydin, Okan Derin, Bahadir Ceylan, Ali Mert |
Abstract |
We present a 35-year-old female patient who was started on rifampicin (900 mg orally once daily) and trimethoprim/sulfamethoxazole (TMP/SMX) (160/800 mg orally twice daily) after being diagnosed with brucellosis. Following defervescence and improvement in her general condition, fever recurred on the 12th day of treatment. A re-challenge drug test lead to causality assessment and treatment was switched to a combination of streptomycin (1 g intramuscularly) for 10 days and TMP/SMX (160/800 mg orally twice daily) for 4 weeks. Our patient is doing well after 12 months of follow-up. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 12 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 1 | 8% |
Librarian | 1 | 8% |
Student > Doctoral Student | 1 | 8% |
Student > Bachelor | 1 | 8% |
Researcher | 1 | 8% |
Other | 1 | 8% |
Unknown | 6 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 25% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
Unspecified | 1 | 8% |
Immunology and Microbiology | 1 | 8% |
Agricultural and Biological Sciences | 1 | 8% |
Other | 0 | 0% |
Unknown | 5 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2018.
All research outputs
#18,587,406
of 23,023,224 outputs
Outputs from Drug Safety - Case Reports
#28
of 42 outputs
Outputs of similar age
#331,978
of 442,600 outputs
Outputs of similar age from Drug Safety - Case Reports
#5
of 7 outputs
Altmetric has tracked 23,023,224 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 42 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.0. This one scored the same or higher as 14 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,600 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.